A Phase 2b study evaluating sabizabulin for the treatment of AR+ ER+ HER2- metastatic breast cancer in patients with an AR nuclei staining <40%
Latest Information Update: 03 Dec 2021
At a glance
- Drugs Sabizabulin (Primary) ; Everolimus; Exemestane
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 03 Dec 2021 New trial record
- 02 Dec 2021 According to a Veru media release,this study is expected to begin in 1Q calendar 2022.